Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Didden, Eva-Maria; Ruffieux, Yann; Hummel, Noemi; Efthimiou, Orestis; Reichenbach, Stephan; Gsteiger, Sandro; Finckh, Axel; Fletcher, Christine; Salanti, Georgia; Egger, Matthias

doi:10.1177/0272989X18775975

Scientific article

English

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

ContributorsDidden, Eva-Maria; Ruffieux, Yann; Hummel, Noemi; Efthimiou, Orestis; Reichenbach, Stephan; Gsteiger, Sandro; Finckh, Axel; Fletcher, Christine; Salanti, Georgia; Egger, Matthias

Published inMedical Decision Making, vol. 38, no. 6, p. 719-729

Publication date2018

Abstract

Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available.

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Citation (ISO format)

DIDDEN, Eva-Maria et al. Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. In: Medical Decision Making, 2018, vol. 38, n° 6, p. 719–729. doi: 10.1177/0272989X18775975

Article (Published version)

Identifiers

PID : unige:110686
DOI : 10.1177/0272989X18775975
PMID : 30074882

ISSN of the journal0272-989X

346views

0downloads

Creation09/03/2018 1:57:00 PM

First validation09/03/2018 1:57:00 PM

Update time03/15/2023 1:12:21 PM

Status update03/15/2023 1:12:20 PM

Last indexation10/19/2023 9:19:54 AM

Archive ouverte UNIGE

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available.

Technical informations